These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 11435064)

  • 1. A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.
    Llovet JM; Ruff P; Tassopoulos N; Castells L; Bruix J; El-Hariry I; Peachey M
    Eur J Cancer; 2001 Jul; 37(11):1352-8. PubMed ID: 11435064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.
    Benson AB; Mitchell E; Abramson N; Klencke B; Ritch P; Burnhan JP; McGuirt C; Bonny T; Levin J; Hohneker J
    Ann Oncol; 2002 Apr; 13(4):576-81. PubMed ID: 12056708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer.
    Rivera E; Sutton L; Colwell B; Graham M; Frye D; Somerville M; Conklin HS; McGuirt C; Levin J; Hortobagyi GN
    J Clin Oncol; 2002 Feb; 20(4):987-93. PubMed ID: 11844821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
    Baker SD; Diasio RB; O'Reilly S; Lucas VS; Khor SP; Sartorius SE; Donehower RC; Grochow LB; Spector T; Hohneker JA; Rowinsky EK
    J Clin Oncol; 2000 Feb; 18(4):915-26. PubMed ID: 10673535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
    Meropol NJ; Niedzwiecki D; Hollis D; Schilsky RL; Mayer RJ;
    Cancer; 2001 Apr; 91(7):1256-63. PubMed ID: 11283924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer.
    Marsh JC; Catalano P; Huang J; Graham DL; Cornfeld MJ; O'Dwyer PJ; Benson AB
    Clin Colorectal Cancer; 2002 May; 2(1):43-50. PubMed ID: 12453335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer.
    Skovsgaard T; Davidson NG; Piccart MJ; Richel DJ; Bonneterre J; Cirkel DT; Barton CM;
    Ann Oncol; 2001 Sep; 12(9):1255-7. PubMed ID: 11697836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
    Schilsky RL; Levin J; West WH; Wong A; Colwell B; Thirlwell MP; Ansari RH; Bell WN; White RL; Yates BB; McGuirt PV; Pazdur R
    J Clin Oncol; 2002 Mar; 20(6):1519-26. PubMed ID: 11896100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
    Ochoa L; Hurwitz HI; Wilding G; Cohen D; Thomas JP; Schwartz G; Monroe P; Petros WP; Ertel VP; Hsieh A; Hoffman C; Drengler R; Magnum S; Rowinsky EK
    Ann Oncol; 2000 Oct; 11(10):1313-22. PubMed ID: 11106122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
    Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
    J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer.
    Mani S; Hochster H; Beck T; Chevlen EM; O'Rourke MA; Weaver CH; Bell WN; White R; McGuirt C; Levin J; Hohneker J; Schilsky RL; Lokich J
    J Clin Oncol; 2000 Aug; 18(15):2894-901. PubMed ID: 10920138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma.
    Rivera E; Valero V; Cristofanilli M; Frye DK; Booser DJ; Rosales MM; Hortobagyi GN
    Cancer; 2002 May; 94(9):2321-6. PubMed ID: 12015755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma.
    de Lima Lopes G; Dicksey JS; Peters WP; Palalay M; Chang AY
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1067-73. PubMed ID: 21344302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.
    Grem JL; Harold N; Shapiro J; Bi DQ; Quinn MG; Zentko S; Keith B; Hamilton JM; Monahan BP; Donavan S; Grollman F; Morrison G; Takimoto CH
    J Clin Oncol; 2000 Dec; 18(23):3952-63. PubMed ID: 11099325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
    Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
    Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of weekly paclitaxel plus prolonged oral eniluracil/5-fluorouracil in patients with refractory malignancies.
    Jones SF; Greco FA; Hainsworth JD; Patton JW; Barton JH; Willcutt NT; Baker MN; McGuirt PV; Levin J; Burris HA
    Oncologist; 2002; 7(5):444-50. PubMed ID: 12401907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dose-escalating study of oral eniluracil/5-fluorouracil plus oxaliplatin in patients with advanced gastrointestinal malignancies.
    Yip D; Karapetis C; Strickland AH; Steer C; Holford C; Knight S; Harper P
    Ann Oncol; 2003 Jun; 14(6):864-6. PubMed ID: 12796023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.
    Rothenberg ML; Benedetti JK; Macdonald JS; Seay TE; Neubauer MA; George CS; Tanaka MS; Giguere JK; Pruitt BT; Abbruzzese JL
    Ann Oncol; 2002 Oct; 13(10):1576-82. PubMed ID: 12377645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.
    Czito BG; Hong TJ; Cohen DP; Tyler DS; Lee CG; Anscher MS; Ludwig KA; Seigler HF; Mantyh C; Morse MA; Lockhart AC; Petros WP; Honeycutt W; Spector NL; Ertel PJ; Mangum SG; Hurwitz HI
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):779-85. PubMed ID: 14967434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study.
    Smith IE; Johnston SR; O'Brien ME; Hickish TF; de Boer RH; Norton A; Cirkel DT; Barton CM
    J Clin Oncol; 2000 Jun; 18(12):2378-84. PubMed ID: 10856097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.